Month: November 2020

Quanta News

John S. Lipman Appointed as Quanta’s President, North America.

Alcester, Warwickshire, UK.  24 November 2020.  Seroba’s portfolio company, Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a medical technology company developing innovative dialysis products and services, has announced the appointment of John S. Lipman as Quanta’s  President, North America. John will lead Quanta’s commercial operations and activities in the United States. He is already …

John S. Lipman Appointed as Quanta’s President, North America. Read More »

Home V2

Storm Therapeutics and Evotec Leverage Indigo Platform to Progress Oncology Project.

Storm’s First-in-Class clinical candidate against an RNA Methyltransferase for use in Cancer was identifed with support from Evotec’s Drug Discovery Engine. Storm will progress the compound towards the clinic using indigo, Evotec’s integrated Ivestigational New Drug (IND) enabling Platform. Hamburg, Germany.  17 November 2020.  Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today …

Storm Therapeutics and Evotec Leverage Indigo Platform to Progress Oncology Project. Read More »

Pq Bypass

PQ Bypass Releases Positive 24-Month Data from the DETOUR1 Clinical Trial.

MILPITAS, Calif.  November 12, 2020.  Seroba’s portfolio company, PQ Bypass, Inc, a medical device pioneer bringing new advancements to the treatment of complex peripheral artery disease (PAD), announced promising long-term safety and effectiveness results from 24-month follow-up data from the DETOUR1 Clinical Study, including a 79% primary patency, with 82% of patients maintaining freedom from …

PQ Bypass Releases Positive 24-Month Data from the DETOUR1 Clinical Trial. Read More »

Heidi Zac Image

Heidi Zak, CEO of ThirdLove, joins INNOVO® in advisory role.

BOSTON, Nov. 10, 2020 Seroba’s portfolio company, Atlantic Therapeutics, has announced that Heidi Zak, co-founder and CEO of ThirdLove will take on an advisory role in the acceleration of the INNOVO® brand. INNOVO® is a direct-to-consumer, FDA-approved medical device offering a clinically proven solution to stress urinary incontinence (SUI).  INNOVO® is poised to disrupt the …

Heidi Zak, CEO of ThirdLove, joins INNOVO® in advisory role. Read More »

Da73c103 A854 419d 8527 Ed1475347af1

Fusion Pharmaceuticals Announces Collaboration With AstraZeneca To Develop And Commercialize Next-Generation Radiopharmaceuticals And Combination Therapies.

Hamilton, Ontario and Boston, 2 November 2020.  Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced a collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) to develop and commercialize next-generation alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. The collaboration leverages Fusion’s Targeted Alpha Therapies (TATs) …

Fusion Pharmaceuticals Announces Collaboration With AstraZeneca To Develop And Commercialize Next-Generation Radiopharmaceuticals And Combination Therapies. Read More »

T: 353 (0)1 633 4028

18 Herbert Street
Dublin 2
D02 FK19
Ireland

Scroll to Top